AbbVie’s Global Bestseller Humira Will Face Counterfeits This Week (NYSE:ABBV)



After generating $208 billion in sales over two decades, AbbVie’s (NYSE: ABBV) monopoly on its world’s best-selling therapy Humira (adalimumab) is about to end this week as copycat versions enter the US market.

A self-administered injection indicated for rheumatoid arthritis iABBVfor the tenth year in a row.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *